Moreover, we studied the antitumor activity of the alkylating agents trabectedin and the PARP1 inhibitor olaparib, observing variable degrees of synergism against advanced sarcomas in preclinical and clinical settings [10, 11]. This evidence concerns the gene PARP1 and sarcoma.